AU2015311799A1 - Topical pterostilbene compositions for use in treating UV-induced loss of barrier function in skin - Google Patents

Topical pterostilbene compositions for use in treating UV-induced loss of barrier function in skin Download PDF

Info

Publication number
AU2015311799A1
AU2015311799A1 AU2015311799A AU2015311799A AU2015311799A1 AU 2015311799 A1 AU2015311799 A1 AU 2015311799A1 AU 2015311799 A AU2015311799 A AU 2015311799A AU 2015311799 A AU2015311799 A AU 2015311799A AU 2015311799 A1 AU2015311799 A1 AU 2015311799A1
Authority
AU
Australia
Prior art keywords
skin
pterostilbene
topical
loss
barrier function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015311799A
Other languages
English (en)
Inventor
Ryan W. DELLINGER
Frank L. Meyskens Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2015311799A1 publication Critical patent/AU2015311799A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
AU2015311799A 2014-09-04 2015-09-03 Topical pterostilbene compositions for use in treating UV-induced loss of barrier function in skin Abandoned AU2015311799A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462046068P 2014-09-04 2014-09-04
US62/046,068 2014-09-04
PCT/US2015/048422 WO2016036999A1 (en) 2014-09-04 2015-09-03 Topical pterostilbene compositions for use in treating uv-induced loss of barrier function in skin

Publications (1)

Publication Number Publication Date
AU2015311799A1 true AU2015311799A1 (en) 2017-03-30

Family

ID=55436471

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015311799A Abandoned AU2015311799A1 (en) 2014-09-04 2015-09-03 Topical pterostilbene compositions for use in treating UV-induced loss of barrier function in skin

Country Status (11)

Country Link
US (1) US9980924B2 (enExample)
EP (1) EP3194032B1 (enExample)
JP (1) JP2017525738A (enExample)
KR (1) KR20170045343A (enExample)
CN (1) CN107106877A (enExample)
AU (1) AU2015311799A1 (enExample)
BR (1) BR112017004304B1 (enExample)
CA (1) CA2959756C (enExample)
MX (1) MX375612B (enExample)
WO (1) WO2016036999A1 (enExample)
ZA (1) ZA201701510B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015311799A1 (en) 2014-09-04 2017-03-30 The Regents Of The University Of California Topical pterostilbene compositions for use in treating UV-induced loss of barrier function in skin
WO2018034328A1 (ja) * 2016-08-17 2018-02-22 香港友池有限公司 プテロスチルベン配糖体を含む外用組成物
JP7061766B2 (ja) * 2017-09-20 2022-05-02 学校法人同志社 Ｄｊ－１タンパク質産生促進用組成物
KR20220123067A (ko) 2019-12-30 2022-09-05 로단 앤드 필즈, 엘엘씨 Ppar 작용제 복합물 및 사용 방법
EP4029496A1 (en) * 2021-01-18 2022-07-20 Universitat de València Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2820975B1 (fr) * 2001-02-21 2004-03-12 Oreal Composition pour application topique comprenant au moins un hydroxystilbene et au moins un polyol pour solubiliser l'hydroxystilbene
US20090047309A1 (en) * 2007-08-13 2009-02-19 Maes Daniel H Cosmetic methods and compositions for repairing human skin
US8703161B2 (en) 2007-08-13 2014-04-22 Elc Management, Llc Skin repair compositions comprising circadian gene activators and a synergistic combination of Sirt1 gene activators
US20100240767A1 (en) * 2009-03-23 2010-09-23 Muhammed Majeed Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof
EP2322159A1 (en) * 2009-10-30 2011-05-18 Green Molecular, S.L. Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic
US8841350B2 (en) * 2011-05-11 2014-09-23 ChromaDex Inc. Method for inducing UDP-glucuronosyltransferase activity using pterostilbene
JP2013075851A (ja) * 2011-09-30 2013-04-25 Fujifilm Corp 皮膚外用剤
US20130296440A1 (en) 2012-05-01 2013-11-07 ChromaDex Inc. Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
CN103239540B (zh) * 2013-04-03 2014-11-12 广东药学院 一种凉血愈伤方提取物及治疗皮肤烧伤的复方白藜芦醇凉血愈伤油制剂
AU2015311799A1 (en) 2014-09-04 2017-03-30 The Regents Of The University Of California Topical pterostilbene compositions for use in treating UV-induced loss of barrier function in skin
WO2016037007A1 (en) 2014-09-04 2016-03-10 The Regents Of The University Of California Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia

Also Published As

Publication number Publication date
EP3194032A4 (en) 2018-05-23
JP2017525738A (ja) 2017-09-07
US20160067194A1 (en) 2016-03-10
WO2016036999A1 (en) 2016-03-10
BR112017004304B1 (pt) 2020-12-08
ZA201701510B (en) 2018-11-28
BR112017004304A2 (pt) 2017-12-05
EP3194032A1 (en) 2017-07-26
CN107106877A (zh) 2017-08-29
MX2017002818A (es) 2017-08-02
CA2959756A1 (en) 2016-03-10
US9980924B2 (en) 2018-05-29
MX375612B (es) 2025-03-06
KR20170045343A (ko) 2017-04-26
EP3194032B1 (en) 2021-06-23
CA2959756C (en) 2023-02-28

Similar Documents

Publication Publication Date Title
Amini et al. Nonsurgical innovations in the treatment of nonmelanoma skin cancer
US9980924B2 (en) Topical pterostilbene compositions for use in treating UV-induced loss of barrier function in skin
Elmets et al. Cutaneous photoprotection from ultraviolet injury by green tea polyphenols
Morgado‐Carrasco et al. Impact of ultraviolet radiation and exposome on rosacea: Key role of photoprotection in optimizing treatment
Yarosh et al. Anti-inflammatory activity in skin by biomimetic of Evodia rutaecarpa extract from traditional Chinese medicine
Tao et al. The Nrf2-inducers tanshinone I and dihydrotanshinone protect human skin cells and reconstructed human skin against solar simulated UV
US8029770B2 (en) Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer
Perugini et al. Efficacy of oleuropein against UVB irradiation: preliminary evaluation
AU3722597A (en) Genistein as a preventive against ultraviolet induced skin photodamage and cancer
Berman et al. Pharmacotherapy of actinic keratosis: an update
CN117377475B (zh) 治疗与糖尿病性周围神经病变相关的疼痛
MX2014013925A (es) Metodo para identificar ligandos del receptor ahr que tienen actividad sebosupresora terapeutica, y los ligandos.
Lyons et al. Mitigating visible light and long wavelength UVA1‐induced effects with topical antioxidants
US10226435B2 (en) Compositions and methods for restoring the stratum corneum and treating dermatological diseases
McDaniel et al. Evaluation of the antioxidant capacity and protective effects of a comprehensive topical antioxidant containing water-soluble, enzymatic, and lipid-soluble antioxidants
Fabbrocini et al. A peel‐off facial mask comprising myoinositol and trehalose‐loaded liposomes improves adult female acne by reducing local hyperandrogenism and activating autophagy
Moglia et al. Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses
US20160067193A1 (en) Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia
Yu et al. Research progress of vitiligo repigmentation: from oxidative stress to autoimmunity
HK1241310B (en) Topical pterostilbene compositions for use in treating loss of barrier function in skin in burn injurys
Kim et al. Chemical stability and in vitro and clinical efficacy of a novel hybrid retinoid derivative, bis-retinamido methylpentane
BRPI0719454A2 (pt) "Método de terapia de manutenção do melasma e uso de uma mistura de fluocinolona acetonida, hidroquinona tretinoína"
Panda et al. Assessment of the SPF and Anti-Irritating Properties of Sunscreen designed for Retinol users
Swenson et al. Therapeutic effect of NEO400, perillyl alcohol conjugated to linoleic acid, in a mouse model of UV‐induced skin damage
Pustišek et al. A review of sunscreens and their adverse reactions

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted